2024年05月15日

The Health and Global Policy Institute (HGPI) Patient and Public Involvement (PPI) Support Project formulated policy recommendations titled, “Promoting PPI in the Policymaking Process.”

In FY2021, HGPI formed an advisory board of experts with experience serving as patient and citizen committee members and other specialists in this area for discussions on promoting PPI in health policy. Based on the findings of those efforts and with cooperation from broad stakeholders including patients and citizens, administrative officials, and academics, who participated in our interviews and other activities, we compiled the “Guidance on PPI in Health Policymaking” in March 2024. In hopes of seeing PPI implemented in the policymaking process as described in that Guidance, these six recommendations summarized specific initiatives that must be taken, especially by central ministries and agencies as well as by local governments.

We hope that our recommendations will help policy makers and stakeholders to more effectively implement patient and public involvement in the policymaking process. For more details, please find the PDF document below.


Recommendations

Recommendation 1: Reserve multiple seats for patient and citizen members so government committees can deliver a diversity of patient and citizen voices to policy.
Recommendation 2: Ensure equal opportunities for involvement in government committees by establishing terms of office for committee members and by disclosing selection criteria for patient and citizen committee members in advance.
Recommendation 3: Enable patient and citizen committee members to effectively participate on government committees by establishing a comprehensive support framework.
Recommendation 4: Draw upon a variety of PPI methods to overcome the limitations of government committees in gathering a broad range of patient and citizen voices.
Recommendation 5: Secure human resources for PPI in the policymaking process by identifying the necessary qualities for taking part in government meetings and developing a training system based on an integrated curriculum.
Recommendation 6: Develop guidelines on implementing PPI to provide a foundation for fair involvement in the policymaking process.

2024年05月09日

*Please note that this program is available in Japanese only

The Health Policy Academy (HPA) is a public lecture series for citizens who want to learn about health policy. It is offered by Health and Global Policy Institute (HGPI), a non-profit, independent think tank. Since the first session in 2015, the HPA has been attended by nearly 400 people. The course has provided content for beginners in health policy through a variety of programs, including lectures by opinion leaders from the public and private sectors, and discussions between students with diverse backgrounds.

The 13th term will be offered under the theme of “Citizenship and Health Policy .” In recent years, there have been many textbooks and courses on health policy, and it has become possible to engage in various opinion exchanges and access content online. On the other hand, health policy is diverse in perspectives among stakeholders, and consensus-building can be challenging. However, the aim of the various systems surrounding healthcare is to support our lives and health and enable us to lead a high-quality of life. At the Health Policy Academy, in line with HGPI’s mission of “Achieving citizen-centered health policy by bringing stakeholders together as an independent think-tank,” we aim to provide an opportunity for students to go beyond their daily positions and engage with health policy as individuals and consider its future direction.

Building on the curriculum renewed in the 12th term, we will offer a curriculum that incorporates more practical content. In addition to the theoretical aspects such as ethics, norms, and how to deal with evidence that form the basis of policy, we will cover practical themes such as the medical service fee schedule and healthcare delivery systems, as well as advocacy activities to convey the direction that healthcare policy should take from the perspective of citizens. Through discussions and group work with students from various backgrounds, you will have the opportunity to experience the ways of thinking necessary for actual policy formation, such as adjusting and reaching consensus among different perspectives.

■Language
Japanese Only

■ Event Format
This event will be held in person at the Global Business Hub Tokyo

■ Location
Global Business Hub Tokyo (Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo, JAPAN)

For more information, please visit the Japanese website.

2024年04月23日

Around the world, alcoholic beverages have played a vital role in shaping local food cultures and are an important source of revenue for governments. However, in addition to mental disorders like alcoholism, alcohol consumption is a known factor for a number of serious non-communicable diseases (NCDs) like cancer, liver disease, and cardiovascular diseases (CVDs) and can lead to social harms such as traffic accidents and violence. In response, some people are calling for action to address Health Problems Caused by Alcohol.

Driven by concern toward the health and social consequences of alcohol, the World Health Organization (WHO) adopted the “Global strategy to reduce the harmful use of alcohol” at the World Health Assembly in 2010. Later, in 2013, the WHO presented a plan aiming to prevent NCDs caused by alcohol consumption titled the “Global action plan for the prevention and control of noncommunicable diseases 2013-2020” (currently the Global Action Plan 2022-2030). In response to these developments, Japan enacted the Basic Act on Measures against Health Problems Caused by Alcohol in December 2013. Based on this law, the Government of Japan formulated the Basic Plan for Promotion of Measures against Health Problems Caused by Alcohol (hereinafter referred to as the “Alcohol Basic Plan”). This is how all of Japan began taking steps to promote measures against alcohol-related health problems. The Alcohol Basic Plan is currently in its second phase (2021-2025) and outlines priorities and ten basic measures to drive progress in reducing alcohol-related harm. In response to that plan, guidelines titled, “Guidelines on Alcohol Consumption Considering Health Issues” were formulated in February 2024 to promote the dissemination of information regarding the risks associated with alcohol consumption.

For the upcoming 125th HGPI Seminar, we will host Dr. Sachio Matsushita, who chaired the study group that prepared the “Guidelines on Alcohol Consumption Considering Health Issues.” Dr. Matsushita will share the history and current state of domestic measures for reducing alcohol-related health problems, the background to the preparation of the “Guidelines on Alcohol Consumption Considering Health Issues,” and future prospects for efforts in this area. In 2025, Japan is set to revise the Alcohol Basic Plan, and on the global stage, NCDs will be discussed at the Fourth High-level Meeting of the United Nations General Assembly (HLM4). At HGPI, we will continue holding discussions on controlling alcohol-related harm and other NCDs like CVDs and kidney disease. We would like for this seminar to be an opportunity to discuss with all those present what measures can be taken to reduce alcohol-related harm within Japan’s health policy.

[Event Overview]

  • Speaker: Dr. Sachio Matsushita (Director, National Hospital Organization Kurihama Medical and Addiction Center and Visiting Professor, Department of Neuropsychiatry, Keio University School of Medicine)
  • Date & Time: Friday, May 24 , 2024; from 18:30-19:45 JST
  • Format: Online (Zoom Webinar)
  • Language: Japanese
  • Participation Fee: Free
  • Capacity: 500 people

■Profile:

Dr. Sachio Matsushita (Director of Kurihama Medical and Addiction Center and Visiting Professor, Department of Neuropsychiatry, Keio University School of Medicine)
After graduating from Keio University School of Medicine, he began his career as a psychiatrist at Kurihama Medical and Addiction Center in 1988. Post-doctoral fellow at the National Institute on Alcohol Abuse and Alcoholism from 1993 to 1995. After returning to Kurihama Medical and Addiction Center in 1995, he received a Ph.D. in psychiatry from the Keio University School of Medicine in 2010. He became deputy director in 2011 and has served as director since 2022. He has chaired the committee of the development of the first drinking guideline in Japan.


2024年04月22日

Health and Global Policy Institute (HGPI) will hold an Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens on 23rd May.

Although health policy spans a wide variety of topics, intractable diseases are one of the most important. While they are often discussed alongside rare diseases, certain aspects of intractable diseases place particularly heavy physical and psychological burdens on patients. We have yet to identify the underlying mechanisms or establish clear treatment methods for intractable diseases. They also require patients to undergo long-term treatment. Japan currently designates 341 conditions as “intractable diseases” and they are estimated to affect over 1 million people.

Starting the compilation of the “Outline of Intractable Disease Measures” in 1972, the Government of Japan has been advancing measures for intractable diseases through the promotion of R&D, improving the healthcare provision system, and supporting patients, mainly through the subsidization of care. After the formation of the Liaison Council for Intractable Disease Treatment and establishment of Intractable Disease Support Centers in each prefecture in 1998, joint efforts with the welfare system have been underway to improve living environments and provide employment support for people living with intractable diseases. The Long-Term Care Insurance System has made it possible to provide long-term care to people who require it due to an intractable disease, and a direction for intractable disease measures that include promoting healthcare and improving the social environment was set by the enactment of the Act on Medical Care for Patients with Intractable Diseases in 2014.

However, measures for intractable diseases face a number of lingering issues. For the healthcare provision system, these include information disparities, in which people do not receive enough of the information they need; long diagnostic delays or diagnosis lag; regional healthcare disparities; and collaboration spanning pediatric healthcare to adult healthcare. There are also a number of actions that should be taken for R&D. For example, we hope to see the establishment of a data aggregation system to further basic research on each disease as well as the promotion of Patient and Public Involvement (PPI) to encourage research that reflects patients’ needs in the development of therapeutics.

At this symposium, we will hold a multi-stakeholder discussion on the nature of intractable disease control to identify issues to address in the future and disseminate those issues to greater society.

 

 

[Event Overview]

  • Date & Time: Thursday, May 23, 2024; from 15:00 to 17:00 (Open 14:45) JST
  • Format: Hybrid (In-Person and Online (Zoom Webinars)); the lecture archive will be available at a later date (Please register for webinar if you would like to watch archive)
  • Venue: Global Business Hub Tokyo Field  >>Access
    (Grand Cube 3F, Otemachi Financial City, 1-9-2, Otemachi, Chiyoda-ku, Tokyo, JAPAN 100-0004)
  • Language: Japanese and English (with simultaneous interpretation)
  • Participation Fee: Free
  • Capacity: Venue about 50 /Online 1,000
  • Organizer: Health and Global Policy Institute (HGPI)
  • Sponsor(in no particular order): Astellas Pharma Inc.; Alexion Pharmaceuticals, Inc.; JCR Pharmaceuticals Co., Ltd.
  • Supported by(in no particular order): Japan Patients Association (JPA); NPO ASrid

*Registration in In-Person closed at 12:00, May 20. Participants will be selected by lot and will be informed of the result on May 20. We appreciate your understanding. Please contact us if you would like to join in-person after registration closed.
**After your registration is completed, a confirmation e-mail will be sent automatically to your e-mail address. If you do not receive it, please send us an e-mail at info@hgpi.org.

 

[Program] (titles omitted)

15:00-15:05 Opening Remarks: Marking the Occasion for Intractable Disease Day
Kunio Tsuji (Standing Director, JPA)
15:05-15:20 Presentation 1: The Past and Future of Measures for Intractable Diseases From the Viewpoint of Civil Society
Yukiko Nishimura (President, NPO ASrid)
15:20-15:35 Presentation 2: Measures for Intractable Diseases in Japan
Masaaki Yokota (Deputy Director, Intractable Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare (MHLW))
15:40-15:55 Presentation 3: Current Initiatives in Intractable Diseases from AMED
Tadayoshi Nakashima (Research Officer, Intractable disease/Rare disease, Rare/Intractable Disease Project, Division of Strategic Planning and Evaluation, Department of Innovative Drug Discovery and Development, The Japan Agency for Medical Research and Development (AMED))
15:55-16:10 Presentation 4: Measures for Intractable Disease in Local Governments
Shizuko Tsushima (Director, Cancer and Disease Control Division, Healthcare and Medical Services Department, Health and Medical Services Bureau, Kanagawa Prefectural Government)
16:10-16:25 Presentation 5: Co-creating Research with Patients and Citizens
Atsushi Kogetsu (Assistant Professor, Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University)
16:30-17:00 Panel Discussion: The Future of Intractable Disease Control from the Perspectives of Patients and Citizens
 

Panelists
Keita Otsubo (Secretary General, JPA)
Atsushi Kogetsu (Assistant Professor, Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University)
Tadayoshi Nakashima (Research Officer, Intractable disease/Rare disease, Rare/Intractable Disease Project, Division of Strategic Planning and Evaluation, Department of Innovative Drug Discovery and Development, The Japan Agency for Medical Research and Development (AMED))
Yukiko Nishimura (President, NPO ASrid)
Masaaki Yokota (Deputy Director, Intractable Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare (MHLW))

Moderator
Shunichiro Kurita (Senior Manager, HGPI)

PageTop